deoxyuridine triphosphate has been researched along with Multiple Myeloma in 1 studies
*Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Z; Chen, L; Gao, S; Li, Q; Liu, S; Ma, J; Wang, Y | 1 |
1 other study(ies) available for deoxyuridine triphosphate and Multiple Myeloma
| Article | Year |
|---|---|
DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Retrospective Studies | 2022 |